ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 397

Comorbidities Associated with Pediatric Psoriatic Arthritis

Cynthia Manos1, Rui Xiao2, Alexis Ogdie3, Timothy Brandon4 and Pamela F. Weiss5,6, 1Rheumatology, Children's Hospital of Philadelphia, Philadelphia, PA, 2Department of Biostatistics and Epidemiology, University of Pennsylvania, Philadelphia, PA, 3University of Pennsylvania, Philadelphia, PA, 4Pediatrics, Children's Hospital of Philadelphia, Philadelphia, PA, 5Department of Pediatrics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, 6Division of Rheumatology, Center for Pediatric Clincial Effectiveness, Children's Hospital of Philadelphia, Philadelphia, PA

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: Diabetes, hypertension, obesity, pediatric rheumatology and psoriatic arthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 13, 2016

Title: Pediatric Rheumatology – Clinical and Therapeutic Aspects - Poster I: Juvenile Idiopathic Arthritis, Uveitis

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: In adults, psoriatic arthritis (PsA) is associated with an increased prevalence of obesity, hypertension, and diabetes.  It is not yet known if pediatric patients with PsA also have a higher prevalence of these comorbidities.  We evaluated the association of obesity, hypertension, and diabetes with PsA and psoriasis in children. 

Methods: We conducted a cross-sectional study of children with PsA and psoriasis enrolled in The Health Improvement Network (THIN) database between 1994 and 2013.  All psoriasis and PsA cases in the cohort had ≥ 1 READ code for psoriasis, or psoriasis and arthritis, respectively.  The index date was defined as the first READ code entry for psoriasis or PsA.  Controls were matched on age, sex, and practice at a 5:1 ratio.  Prevalence of hypertension, diabetes, and obesity were calculated among patients in these groups.   Hypertension and diabetes were identified using ≥ 1 READ code for these diagnoses.  Age- and sex-specific z-scores for BMI (zBMI) were calculated.  Differences in demographic and clinical characteristics were assessed using the t-test and Wilcoxon rank sum test, as appropriate. 

Results: 6366, 1786, and 13351 children were identified as having juvenile arthritis (excluding PsA), PsA, and psoriasis, respectively.  Among children with psoriasis, 280 (2.1%) had PsA.   The mean age at PsA diagnosis was 7.7 (SD 4.5) years and psoriasis diagnosis was 9.8 (SD 4.0) years.  62.4% of the PsA, 56.7% of the psoriasis, and 56.5% of the controls were female.  Table 1 summarizes characteristics of each patient population at the time of data collection.  PsA patients were significantly more likely to have hypertension and diabetes than patients with psoriasis, but did not have a higher prevalence of hypertension and had a lower prevalence of diabetes compared to controls.  zBMI was significantly higher in PsA compared to controls (1.1 vs 0.07, p-value 0.03) and psoriasis compared to controls (0.9 vs 0.07, p-value 0.01), but not significantly different between children with PsA and psoriasis (p-value 0.3).

Conclusion: PsA was found to be associated with an increased prevalence of hypertension and diabetes compared to patients with psoriasis, but not compared to healthy controls.  Children with PsA and psoriasis also had a significantly higher mean zBMI compared to healthy controls. 

 


Disclosure: C. Manos, Mallinckrodt Pharmaceuticals, 2; R. Xiao, None; A. Ogdie, None; T. Brandon, None; P. F. Weiss, None.

To cite this abstract in AMA style:

Manos C, Xiao R, Ogdie A, Brandon T, Weiss PF. Comorbidities Associated with Pediatric Psoriatic Arthritis [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/comorbidities-associated-with-pediatric-psoriatic-arthritis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/comorbidities-associated-with-pediatric-psoriatic-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology